Lyell Immunopharma Shares Owned By Insiders vs. Total Debt
| LYEL Stock | USD 0.95 0.03 3.26% |
For Lyell Immunopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lyell Immunopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lyell Immunopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lyell Immunopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lyell Immunopharma over time as well as its relative position and ranking within its peers.
Lyell |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lyell Immunopharma Total Debt vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lyell Immunopharma's current stock value. Our valuation model uses many indicators to compare Lyell Immunopharma value to that of its competitors to determine the firm's financial worth. Lyell Immunopharma is rated below average in shares owned by insiders category among its peers. It is rated below average in total debt category among its peers making up about 4,492,355 of Total Debt per Shares Owned By Insiders. The value of Total Debt To Capitalization is expected to slide to 0.06. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lyell Immunopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Lyell Total Debt vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Lyell Immunopharma |
| = | 14.06 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Lyell Immunopharma |
| = | 63.17 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Lyell Total Debt vs Competition
Lyell Immunopharma is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 940.6 Million. Lyell Immunopharma holds roughly 63.17 Million in total debt claiming about 7% of equities under Health Care industry.
Lyell Immunopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lyell Immunopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lyell Immunopharma will eventually generate negative long term returns. The profitability progress is the general direction of Lyell Immunopharma's change in net profit over the period of time. It can combine multiple indicators of Lyell Immunopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -94 K | -98.7 K | |
| Net Interest Income | 23.5 M | 24.6 M | |
| Interest Income | 23.5 M | 24.6 M | |
| Operating Income | -247 M | -259.4 M | |
| Net Loss | -234.6 M | -246.4 M | |
| Income Before Tax | -234.6 M | -246.4 M | |
| Total Other Income Expense Net | 12.4 M | 13 M | |
| Net Loss | -164.8 M | -173 M | |
| Net Loss | -234.6 M | -246.4 M | |
| Income Tax Expense | -10.5 M | -11.1 M | |
| Non Operating Income Net Other | -32.9 M | -34.6 M | |
| Change To Netincome | 89.2 M | 75.4 M | |
| Net Loss | (0.93) | (0.98) | |
| Income Quality | 0.70 | 0.42 | |
| Net Income Per E B T | 0.03 | 0.03 |
Lyell Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lyell Immunopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lyell Immunopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lyell Immunopharma's important profitability drivers and their relationship over time.
Use Lyell Immunopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lyell Immunopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyell Immunopharma will appreciate offsetting losses from the drop in the long position's value.Lyell Immunopharma Pair Trading
Lyell Immunopharma Pair Trading Analysis
The ability to find closely correlated positions to Lyell Immunopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lyell Immunopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lyell Immunopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lyell Immunopharma to buy it.
The correlation of Lyell Immunopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lyell Immunopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lyell Immunopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lyell Immunopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lyell Immunopharma position
In addition to having Lyell Immunopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Farming Thematic Idea Now
Farming
Companies producing farming products and providing services for farmers. The Farming theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Farming Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
To fully project Lyell Immunopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lyell Immunopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lyell Immunopharma's income statement, its balance sheet, and the statement of cash flows.